JANX — Janux Therapeutics Share News
0.000.00%
Last trade - 00:00- $1.04bn
- $72.08m
- $10.00m
Brief: Janux Therapeutics Announces First Patient Dosed In Early-Stage Trial
U.S. RESEARCH ROUNDUP-Huntington Bancshares, Popular, Welltower
Brief: Janux Therapeutics Reports Fourth Quarter And Full Year 2022 Financial Results
Brief: Janux Therapeutics reports Q4 collaboration revenue USD 2.845 million
Brief: Janux Therapeutics Announces Submission Of Investigational New Drug Application For Janx008
Brief: Janux Therapeutics Reports Third Quarter 2022 Financial Results, Business Highlights
Brief: Janux Therapeutics Announces First Patient Dosed With Janx007 In First-In-Human Phase 1 Clinical Trial In Patients With Prostate Cancer
Brief: Janux Therapeutics Appoints Brenda Vreeswyk As Head Of HR
Brief: Janux Therapeutics Appoints Winston Kung To Board Of Directors
Brief: Janux Therapeutics Files For Mixed Shelf Of Up To $400 Mln
Brief: Janux Therapeutics Reports Second Quarter 2022 Financial Results
Brief: Janux Therapeutics Announces FDA Clearance Of Investigational New Drug Application For Janx007
Brief: Janux Therapeutics Reports First Quarter 2022 Results And Business Highlights
Brief: Janux Therapeutics Posts Qtrly Loss Per Share $0.33
Brief: Janux Therapeutics Posts Q3 Loss Per Share Of $0.26
Brief: Janux Therapeutics Appoints Ron Barrett And Alana Mcnulty To Board Of Directors
Janux Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Janux Therapeutics Reports Second Quarter 2021 Financial Results
Brief: Orbimed Advisors Llc Reports 7.3% Stake In Janux Therapeutics Inc As Of June 15